TY  - JOUR
AU  - Kerns, Sarah L
AU  - Amidon Morlang, Ashley
AU  - Lee, Sharon M
AU  - Peterson, Derick R
AU  - Marples, Brian
AU  - Zhang, Hong
AU  - Bylund, Kevin
AU  - Rosenzweig, Doug
AU  - Hall, William
AU  - De Ruyck, Kim
AU  - Rosenstein, Barry S
AU  - Stock, Richard G
AU  - Gómez-Caamaño, Antonio
AU  - Vega, Ana
AU  - Sosa-Fajardo, Paloma
AU  - Taboada-Valladares, Begoña
AU  - Aguado-Barrera, Miguel E
AU  - Parker, Chris
AU  - Veldeman, Liv
AU  - Fonteyne, Valérie
AU  - Bultijnck, Renée
AU  - Talbot, Christopher J
AU  - Paul Symonds, R.
AU  - Johnson, Kerstie
AU  - Rattay, Tim
AU  - Webb, Adam
AU  - Lambrecht, Maarten
AU  - de Ruysscher, Dirk
AU  - Vanneste, Ben
AU  - Choudhury, Ananya
AU  - Elliott, Rebecca M
AU  - Sperk, Elena
AU  - Herskind, Carsten
AU  - Veldwijk, Marlon R
AU  - Rancati, Tiziana
AU  - Avuzzi, Barbara
AU  - Valdagni, Riccardo
AU  - Azria, David
AU  - Farcy Jacquet, Marie-Pierre
AU  - Chang-Claude, Jenny
AU  - Seibold, Petra
AU  - West, Catharine
AU  - Janelsins, Michelle
AU  - Chen, Yuhchyau
AU  - Messing, Edward
AU  - Morrow, Gary
AU  - Azria, David
AU  - Briers, Erik
AU  - Chang-Claude, Jenny
AU  - Choudhury, Ananya
AU  - Dunning, Alison
AU  - Elliott, Rebecca M
AU  - Gutiérrez-Enríquez, Sara
AU  - Rancati, Tiziana
AU  - Rattay, Tim
AU  - Rosenstein, Barry S
AU  - De Ruysscher, Dirk
AU  - Seibold, Petra
AU  - Sperk, Elena
AU  - Paul Symonds, R.
AU  - Stobart, Hilary
AU  - Talbot, Christopher J
AU  - Vega, Ana
AU  - Veldeman, Liv
AU  - Ward, Tim
AU  - Webb, Adam
AU  - West, Catharine M
TI  - Use of Angiotensin Converting Enzyme Inhibitors is Associated with Reduced Risk of Late Bladder Toxicity Following Radiotherapy for Prostate Cancer.
JO  - Radiotherapy and oncology
VL  - 168
SN  - 0167-8140
CY  - Amsterdam [u.a.]
PB  - Elsevier Science
M1  - DKFZ-2022-00170
SP  - 75-82
PY  - 2022
N1  - Volume 168, March 2022, Pages 75-82
AB  - Genome-wide association studies (GWAS) of late hematuria following prostate cancer radiotherapy identified single nucleotide polymorphisms (SNPs) near AGT, encoding angiotensinogen. We tested the hypothesis that patients taking angiotensin converting enzyme inhibitors (ACEi) have a reduced risk of late hematuria. We additionally tested genetically-defined hypertension.Prostate cancer patients undergoing potentially-curative radiotherapy were enrolled onto two multi-center observational studies, URWCI (N=256) and REQUITE (N=1,437). Patients were assessed pre-radiotherapy and followed prospectively for development of toxicity for up to four years. The cumulative probability of hematuria was estimated by the Kaplan-Meier method. Multivariable grouped relative risk models assessed the effect of ACEi on time to hematuria adjusting for clinical factors and stratified by enrollment site. A polygenic risk score (PRS) for blood pressure was tested for association with hematuria in REQUITE and our Radiogenomics Consortium GWAS.Patients taking ACEi during radiotherapy had a reduced risk of hematuria (HR 0.51, 95
LB  - PUB:(DE-HGF)16
C6  - pmid:35077710
DO  - DOI:10.1016/j.radonc.2022.01.014
UR  - https://inrepo02.dkfz.de/record/178629
ER  -